Clinical Trial Update: Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carboplatin, paclitaxel, and bevacizumab in locally recurrent or metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Loyola University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-09-14